Last reviewed · How we verify
NCT07176000
Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial
NA trial testing Patient Navigation in Lung Carcinoma in 237 participants. Not yet recruiting.
29 March 2029
Quick facts
| Lead sponsor | Fred Hutchinson Cancer Center |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 237 |
| Start date | 1 June 2026 |
| Primary completion | 29 March 2029 |
| Estimated completion | 30 April 2029 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Patient Navigation
- Educational Intervention
- Best Practice
- Interview
- Survey Administration
- Electronic Health Record Review
Conditions studied
- Lung Carcinoma — all drugs for Lung Carcinoma →
Sponsor
Fred Hutchinson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial studies whether tailored patient navigation (PN) works to improve the uptake of lung cancer screening (LCS) in tribal communities in western Washington state. Lung cancer is the leading cause of cancer death in the United States among American Indian (AI) and Alaska Native (AN) people, and the incidence of lung cancer is higher in this population in the Northern and Southern Plains, Alaska, and Pacific Coast regions. In Washington state, AI/AN people also have twice the rate of commercial cigarette smoking than the overall population. LCS with annual low-dose chest computed tomography (CT) can reduce lung cancer death and is recommended in people 50-80 years of age with current or recent (within 15 years) tobacco use and a 20 pack-year or greater smoking history. Despite this, AI and AN people are less likely to receive LCS which may be due to barriers they face making it difficult to receive LCS. PN services are designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care. The PN services in this trial have been tailored for the tribal communities in western Washington state. The services are designed to help participants overcome the unique barriers that their tribal communities face and improve the uptake of LCS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07176000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Patient Navigation
Trials testing the same drug.
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer · NA · recruiting
- NCT06995924 — Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education · NA · recruiting
- NCT07052630 — Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoieti · NA · recruiting
- NCT06950008 — A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer · NA · recruiting
Other recruiting trials for Lung Carcinoma
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07019675 — A Study of SKB518 in Patients With Lung Cancer · Phase 2 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
Other Fred Hutchinson Cancer Center trials
Trials by the same sponsor.
- NCT07390968 — Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Pati · Phase 2 · not yet recruiting
- NCT07493252 — A Behavioral Application for Improving Smoking Cessation Among Smokers · NA · not yet recruiting
- NCT07490860 — A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to · NA · not yet recruiting
- NCT07194980 — Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small L · Phase 2 · not yet recruiting
- NCT06926062 — Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07176000 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fred Hutchinson Cancer Center
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07176000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing